Navigation Links
EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
Date:3/25/2008

ROCKVILLE, Md., March 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BioCentury Future Leaders in the Biotech Industry Conference, to be held at the Millennium Broadway Hotel & Conference Center, March 27, 2008. Mr. Burns' presentation is scheduled for Thursday, March 27, 2008 at 4:00 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, is in a Phase 1 study in advanced cancer patients, and ENMD-2076, a selective kinase inhibitor, is expected to begin a Phase 1 study in 2Q08. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Ginny Dunn

Associate Director

Corporate Communications & Investor Relations

EntreMed, Inc.

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EntreMed Announces 2008 Corporate and Clinical Program Priorities
2. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
3. EntreMed to Present at BIO CEO and Investor Conference
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
6. EntreMed Appoints Senior Vice President of Research and Development
7. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
8. Osteotech to Present at the Sidoti Conference in New York
9. BioMS Medical to present at BioCentury Conference
10. Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
11. Evotec AG: Fiscal Year 2007 Results Presentation on March 28, 2008 Live on the Internet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... ... Bacterial biofilms, surface adherent communities of bacteria that are encased in a ... and catheter infections to gum disease and the rejection of medical implants. Though ... year, there is currently a paucity of means for preventing their formation or treating ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... it is exhibiting in booth B2 at the Association for Pathology Informatics ... , In addition to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. ... 2017 at the Prince Of Wales Private Hospital. The procedure was performed on ... The patient failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic ...
(Date:5/18/2017)... Massachusetts (PRWEB) , ... May 17, 2017 , ... ... company specializing in medical device compliance and commercialization, has just released version 9.0 ... of work into this latest version of Cockpit,” says David Cronin, CEO of ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):